STOCK TITAN
  1. Home
  2. Sec-filings
  3. HALO
  4. [Form 4] HALOZYME THERAPEUTICS, INC. Insider Trading Activity

Halozyme (NASDAQ: HALO) CEO sells 50K shares after exercising 50K options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported a series of insider trades in early June 2026. She sold 50,000 shares of common stock in open-market transactions at prices in the mid-to-high $60s per share, according to the Form 4 data.

On the same dates, she exercised 50,000 stock options with an exercise price of $12.07 per share that were due to expire in February 2027. After these transactions, she directly holds 777,780 shares of Halozyme common stock and retains 1,923 options with a $12.07 exercise price expiring in 2027.

The footnotes state that the option exercises and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025, indicating the timing of these trades was set in advance.

Positive

  • None.

Negative

  • None.
Insider Torley Helen
Role PRESIDENT AND CEO
Sold 50,000 shs ($3.37M)
Type Security Shares Price Value
Exercise Option to Purchase Common Stock 10,000 $12.07 $121K
Exercise Common Stock 10,000 $12.07 $121K
Sale Common Stock 400 $66.368 $27K
Sale Common Stock 1,500 $67.675 $102K
Sale Common Stock 2,000 $68.736 $137K
Sale Common Stock 6,100 $69.692 $425K
Exercise Option to Purchase Common Stock 20,000 $12.07 $241K
Exercise Common Stock 20,000 $12.07 $241K
Sale Common Stock 16,600 $66.314 $1.10M
Sale Common Stock 3,400 $66.745 $227K
Exercise Option to Purchase Common Stock 20,000 $12.07 $241K
Exercise Common Stock 20,000 $12.07 $241K
Sale Common Stock 1,610 $66.388 $107K
Sale Common Stock 12,989 $67.41 $876K
Sale Common Stock 5,401 $68.346 $369K
Holdings After Transaction: Option to Purchase Common Stock — 1,923 shares (Direct, null); Common Stock — 777,780 shares (Direct, null)
Footnotes (1)
  1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.840 to $66.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.840 to $67.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.840 to $68.820. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.630 to $66.625. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.630 to $67.180. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.000 to $66.770. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.090 to $68.000. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.100 to $69.080. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.120 to $70.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.
Shares sold 50,000 shares Open-market sales over June 1–3, 2026
Shares from options exercised 50,000 shares Stock option exercises coded M in early June 2026
Option exercise price $12.07 per share Stock options expiring February 22, 2027
Post-transaction share holdings 777,780 shares Common stock held directly after reported trades
Remaining options 1,923 options Options to purchase common stock at $12.07, expiring 2027
Representative sale price $69.692 per share One of the reported weighted average sale prices
Rule 10b5-1 regulatory
"made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted average sales price per share financial
"Represents a weighted average sales price per share. The shares were sold at prices ranging"
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
Option to Purchase Common Stock financial
"security_title": "Option to Purchase Common Stock""
ten-year term expiring in February 2027 financial
"stock options with a ten-year term expiring in February 2027"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Torley Helen
(Last)(First)(Middle)
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
PRESIDENT AND CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/01/2026M(1)20,000A$12.07787,780D
Common Stock06/01/2026S(1)1,610D$66.388(2)786,170D
Common Stock06/01/2026S(1)12,989D$67.41(3)773,181D
Common Stock06/01/2026S(1)5,401D$68.346(4)767,780D
Common Stock06/02/2026M(1)20,000A$12.07787,780D
Common Stock06/02/2026S(1)16,600D$66.314(5)771,180D
Common Stock06/02/2026S(1)3,400D$66.745(6)767,780D
Common Stock06/03/2026M(1)10,000A$12.07777,780D
Common Stock06/03/2026S(1)400D$66.368(7)777,380D
Common Stock06/03/2026S(1)1,500D$67.675(8)775,880D
Common Stock06/03/2026S(1)2,000D$68.736(9)773,880D
Common Stock06/03/2026S(1)6,100D$69.692(10)767,780D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase Common Stock$12.0706/01/2026M(1)20,000 (11)02/22/2027Common Stock20,000$12.0731,923D
Option to Purchase Common Stock$12.0706/02/2026M(1)20,000 (11)02/22/2027Common Stock20,000$12.0711,923D
Option to Purchase Common Stock$12.0706/03/2026M(1)10,000 (11)02/22/2027Common Stock10,000$12.071,923D
Explanation of Responses:
1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.840 to $66.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.840 to $67.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.840 to $68.820. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.630 to $66.625. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.630 to $67.180. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.000 to $66.770. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.090 to $68.000. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
9. Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.100 to $69.080. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
10. Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.120 to $70.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
11. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.
Remarks:
/s/ James R. Oehler, Attorney-in-Fact06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did HALO CEO Helen Torley report on this Form 4?

Helen Torley reported selling 50,000 shares of Halozyme common stock and exercising 50,000 stock options. The sales occurred in open-market transactions over June 1–3, 2026 at prices generally in the mid-to-high $60s per share.

At what prices did the HALO CEO sell shares according to the Form 4?

The Form 4 shows open-market sales at weighted average prices around $66–$70 per share. Footnotes note specific ranges, such as $65.840–$66.830 and $69.120–$70.050, with detailed trade breakdowns available from the company or the SEC on request.

What stock options did Helen Torley exercise in this HALO Form 4 filing?

She exercised options for a total of 50,000 shares of Halozyme common stock at an exercise price of $12.07 per share. The footnotes describe these as stock options with a ten-year term expiring in February 2027 and originally granted in February 2017.

How many HALO shares does the CEO hold after these Form 4 transactions?

Following the reported trades, Helen Torley directly holds 777,780 shares of Halozyme common stock. The filing also shows 1,923 remaining stock options with a $12.07 exercise price expiring in February 2027, reflecting her continuing equity exposure.

Were the HALO CEO’s trades made under a Rule 10b5-1 trading plan?

Yes. A Form 4 footnote states the option exercises and related sales were conducted under a written Rule 10b5-1 trading plan. The plan was adopted on March 21, 2025, meaning the timing of these transactions was pre-arranged rather than decided spontaneously.

What is the net effect of the HALO CEO’s Form 4 trades on her share position?

The transaction summary shows 50,000 shares sold and 50,000 shares acquired through option exercises, resulting in net-sell activity of 50,000 shares. After these movements, she directly holds 777,780 shares and retains additional stock options with a $12.07 exercise price.